慢加急性肝衰竭临床药物治疗研究进展

摘要/Abstract

摘要： 慢加急性肝衰竭(ACLF)是发生在慢性肝病基础上的急性肝损伤,具有潜在的可逆性,但往往病情进展迅速,即使经过治疗,病死率仍居高不下。ACLF的治疗主要包括内科综合治疗、肝脏支持治疗、肝移植治疗,其中肝移植治疗虽然是最有效的治疗手段,但鉴于肝源紧缺、费用高昂、手术风险大等原因限制了其应用。为提高ACLF存活率亟需寻求新的治疗手段,包括干细胞移植、粒细胞集落刺激因子注射、白介素-22等肝再生相关治疗已在临床试验中显示出可观的应用前景,本文就ACLF肝再生相关治疗进展进行综述。

关键词: 慢加急性肝衰竭, 干细胞, 粒细胞集落刺激因子, 白介素-22

徐曼曼, 陈煜. 慢加急性肝衰竭临床药物治疗研究进展[J]. 肝脏, 2022, 27(11): 1238-1242.

参考文献

[1] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019.
[2] Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol, 2014, 61(5): 1038-1047.
[3] Bajaj JS, O'Leary J G, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60(1): 250-256.
[4] Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failur. Gastroenterology, 2014, 147(1): 4-10.
[5] Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-Chronic Liver Failure Clinical Guidelines. Am J Gastroenterol, 2022.
[6] H Zhong, H Zhong. Guideline for diagnosis and treatment of liver failure. Chinese Journal of Hepatology, 2019, 27(1): 18-26.
[7] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 中华肝脏病杂志, 2019, 27(1): 18-26.
[8] Shubham S, Kumar D, Rooge S, et al. Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure. Hepatol Int, 2019, 13(6): 777-787.
[9] Huang W, Han N, Du L, et al. A narrative review of liver regeneration-from models to molecular basis. Ann Transl Med, 2021, 9(22): 1705.
[10] Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology, 2017, 65(4): 1384-1392.
[11] Sun R, Gao B. Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma). Gastroenterology, 2004, 127(5): 1525-1539.
[12] Lee CW, Chen YF, Wu HH, et al. Historical Perspectives and Advances in Mesenchymal Stem Cell Research for the Treatment of Liver Diseases. Gastroenterology, 2018, 154(1): 46-56.
[13] 白佳萌,刘光伟,谢露,等. 间充质干细胞及其外泌体在肝再生领域的应用. 中国组织工程研究, 2022, 26(19): 3071-3077.
[14] Chen B, Wang YH, Qian JQ, et al. Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis. Eur J Gastroenterol Hepatol, 2018, 30(10): 1224-1229.
[15] He Y, Guo X, Lan T, et al. Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1/Stat3 signaling. Stem Cell Res Ther, 2021, 12(1): 396.
[16] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med, 2012, 1(10): 725-731.
[17] Lin BL, Chen JF, Qiu WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology, 2017, 66(1): 209-219.
[18] Li YH, Xu Y, Wu HM, et al. Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation in Hepatitis B Virus Related Acute-on-Chronic Liver Failure Treated with Plasma Exchange and Entecavir: a 24-Month Prospective Study. Stem Cell Rev Rep, 2016, 12(6): 645-653.
[19] Schacher FC, Martins PDSA, Silla L, et al. Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial. Can J Gastroenterol Hepatol, 2021, 2021: 3662776.
[20] Gotze T, Krueger M, Meutsch J, et al. Three Cases of Alcohol-Induced Acute-On-Chronic Liver Failure With Successful Support by Adipose-Derived Stem Cells. Clin Transl Gastroenterol, 2019, 10(12): e95.
[21] Nevens F, Gustot T, Laterre PF, et al. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Rep, 2021, 3(4): 100291.
[22] Zhou GP, Jiang YZ, Sun LY, et al. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2020, 11(1): 419.
[23] Engelmann C, Splith K, Berg T, et al. Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure. Eur J Intern Med, 2016, 36: e37-e39.
[24] Engelmann C, Martino VD, Kerbert A, et al. The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure. Semin Liver Dis, 2021, 41(3): 298-307.
[25] Nam HH, Jun DW, Jang K, et al. Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization. Oncotarget, 2017, 8(58): 97965-97976.
[26] Tsolaki E, Athanasiou E, Gounari E, et al. Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury. Blood Cells Mol Dis, 2014, 53(3): 124-132.
[27] Theocharis SE, Papadimitriou LJ, Retsou ZP, et al. Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy. Dig Dis Sci, 2003, 48(9): 1797-1803.
[28] Piscaglia AC, Shupe TD, Oh SH, et al. Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology, 2007, 133(2): 619-631.
[29] Chavez-Tapia NC, Mendiola-Pastrana I, Ornelas-Arroyo VJ, et al. Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis. Ann Hepatol, 2015, 14(5): 631-641.
[30] Saha BK, Mahtab MA, Akbar S, et al. Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage. Hepatol Int, 2017, 11(6): 540-546.
[31] Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology, 2012, 142(3): 505-512.
[32] Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol, 2013, 19(7): 1104-1110.
[33] Engelmann C, Herber A, Franke A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). J Hepatol, 2021, 75(6): 1346-1354.
[34] Gao B, Xiang X. Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol, 2019, 16(7): 666-667.
[35] Tang KY, Lickliter J, Huang ZH, et al. Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol, 2019, 16(5): 473-482.
[36] Ashour T H. Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure. Adv Hematol, 2014, 2014: 705290.
[37] Mo R, Lai R, Lu J, et al. Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. Theranostics, 2018, 8(15): 4170-4180.
[38] Xiang X, Feng D, Hwang S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol, 2020, 72(4): 736-745.